Co-infections of chickens with avian influenza virus H9N2 and Moroccan Italy 02 infectious bronchitis virus: effect on pathogenesis and protection conferred by different vaccination programmes.
Animals
Antibodies, Viral
/ blood
Chick Embryo
Chickens
Coinfection
/ prevention & control
Coronavirus Infections
/ prevention & control
Infectious bronchitis virus
Influenza A Virus, H9N2 Subtype
Influenza in Birds
/ prevention & control
Lung
/ pathology
Morocco
Oropharynx
/ virology
Pilot Projects
Poultry Diseases
/ prevention & control
RNA, Viral
/ chemistry
Real-Time Polymerase Chain Reaction
/ veterinary
Specific Pathogen-Free Organisms
Trachea
/ pathology
Vaccination
/ veterinary
Vaccines, Attenuated
Viral Vaccines
Virus Shedding
Morocco
avian influenza virus H9N2
commercial broilers
infectious bronchitis virus
specific pathogen free chickens
vaccination
Journal
Avian pathology : journal of the W.V.P.A
ISSN: 1465-3338
Titre abrégé: Avian Pathol
Pays: England
ID NLM: 8210638
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
pubmed:
16
8
2019
medline:
20
5
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
Since the emergence of low pathogenic avian influenza (LPAI) H9N2 viruses in Morocco in 2016, severe respiratory problems have been encountered in the field. Infectious bronchitis virus (IBV) is often detected together with H9N2, suggesting disease exacerbation in cases of co-infections. This hypothesis was therefore tested and confirmed in laboratory conditions using specific-pathogen-free chickens. Most common field vaccine programmes were then tested to compare their efficacies against these two co-infecting agents. IBV γCoV/chicken/Morocco/I38/2014 (Mor-IT02) and LPAI virus A/chicken/Morocco/SF1/2016 (Mor-H9N2) were thus inoculated to commercial chickens. We showed that vaccination with two heterologous IBV vaccines (H120 at day one and 4/91 at day 14 of age) reduced the severity of clinical signs as well as macroscopic lesions after simultaneous experimental challenge. In addition, LPAI H9N2 vaccination was more efficient at day 7 than at day 1 in limiting disease post simultaneous challenge.
Identifiants
pubmed: 31412705
doi: 10.1080/03079457.2019.1656328
doi:
Substances chimiques
Antibodies, Viral
0
RNA, Viral
0
Vaccines, Attenuated
0
Viral Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM